Nurse with her face mask on


Monoclonal Antibodies FAQs


Keri Barclay

Keri Barclay

Manager of Clinical Preparedness/Coalition Administrative Liaison





  • COVID-19
  • Workforce


COVID-19 guide

Updated: Dec. 2, 2021

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.1  “Monoclonal antibodies are basically antibodies that will attach to the spike protein of the SARS-CoV-2 virus (the virus that causes COVID-19). What it does is once it attaches to that spike protein, the virus cannot attach itself to the cells, thereby limiting the spread of the infection and preventing it from progressing further.”2

There currently are two therapies — bamlanivimab, and casirivimab and imdevimab — that have an emergency use authorization from the U.S. Food and Drug Administration for treatment of COVID-19. Additional details are below.

Monoclonal Antibody Therapies

Regional Infusion Centers

Monoclonal antibody infusions continue to be a sound strategy to reduce COVID-19 hospitalizations, and when utilized by community partners, may reduce additional strain on health care operations. To assist with these efforts, MHA compiled a list of Regional mAb Infusion Centers, including their location and contact information


What’s the difference between convalescent plasma and monoclonal antibodies?

Basically, monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. Convalescent plasma is from patients who already have recovered from COVID-19 and may contain antibodies against the virus.

How do I request mAb for my facility?

As of Sept. 13, 2021, the federal government resumed managing the distribution and allocation of monoclonal antibodies to the states. The Missouri Department of Health and Senior Services has been charged with the allocation of the product to administering facilities within the state. This allocation includes both the REGEN-COV (casirivimab and imdevimab) and the Eli Lilly cocktail of bamlanivimab/etesevimab.

The federal and state distributions are based upon data that is entered into TeleTracking weekly. It is imperative that if a facility or clinic is administering mAb to accurately report the amount of product on hand and the number of treatments administered over the past week. TeleTracking guidance on this issue is available.

  • Every Monday by 5 p.m., all orders are due to the state through an online platform.
  • Allocations from DHSS will be made on Wednesday and Thursday of the same week.
  • Notification and shipping will continue to come from AmerisourceBergen to allow planning for the following week’s infusions.

New infusion locations can identify themselves when placing their initial order into the DHSS platform.

Additional information, including a webinar addressing this new process, is available.

What additional information is available to assist with decision-making and operational Implementation of this treatment for COVID-19?

Back to Top